Affiliation:
1. Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA
Abstract
Human fungal infections (mycoses) cause significant morbidity and mortality in high-risk populations. Contemporary antifungal therapies rely heavily on three classes of antifungal drugs, and to date, no fungal vaccine is in clinical use for invasive mycosis.
Funder
HHS | NIH | National Institute of Allergy and Infectious Diseases
Cystic Fibrosis Foundation
Publisher
American Society for Microbiology